Nordwand Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Nordwand Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,000	Closed	-$2.95K	–	116
2024 Q4	$2.95K	Hold	4,000	–	–	﹤0.01%	106
2024 Q3	$6.28K	Hold	4,000	–	–	﹤0.01%	100
2024 Q2	$6.72K	Hold	4,000	–	–	﹤0.01%	119
2024 Q1	$9.6K	Buy	+4,000	New	+$8.59K	﹤0.01%	126

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nordwand Advisors's LXRX Position: Q1 2025 in Review

Nordwand Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 4,000 shares — an estimated $2.95K sold.

Nordwand Advisors first reported a position in LXRX in Q1 2024 and held it in 4 quarters. The position peaked at $9.6K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

Nordwand Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Nordwand Advisors sold 4,000 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $2.95K.
Nordwand Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Nordwand Advisors's Lexicon Pharmaceuticals position peaked at $9.6K in Q1 2024.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Nordwand Advisors's 13F filing for Q1 2025, filed 12 May 2025.